Elsevier

Pharmacological Research

Volume 40, Issue 3, September 1999, Pages 281-286
Pharmacological Research

Regular Article
PHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)

https://doi.org/10.1006/phrs.1999.0509Get rights and content

Abstract

The pharmacokinetics of doxorubicin incorporated as ion-pair into solid lipid nanospheres (SLN) was compared with that of the commercial solution of the drug. Male albino rats (Wistar-derived strain) were treated i.v. with equivalent doses (6 mg kg−1) of two different doxorubicin formulations: an aqueous dispersion of SLN carrying doxorubicin and a commercial doxorubicin solution (Adriablastina®). These formulations were injected, under general anaesthesia, through a cannula into the jugular vein and blood samples were collected at 1, 15, 30, 45, 60, 120 and 180 min after administration. After 180 min rats were killed and samples of liver, heart, lung, kidney, spleen and brain were collected. Blood and tissue samples were analysed by a spectrofluorimetric method. The anthracycline concentration in the blood was markedly higher at each point times with the SLN than with the commercial solution. The drug concentration was also higher in the lung, spleen and brain. SLN-treated rats showed a lower doxorubicin concentration in liver, heart and kidney. The results showed that SLN increased the area under the curve (0–180 min) of doxorubicin compared to conventional doxorubicin solution and led to a different body distribution profile.

References (21)

There are more references available in the full text version of this article.

Cited by (115)

  • Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity

    2020, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    Moreover, lowering pH decreases the distribution coefficient (log D) of DOX, favoring its partition into the aqueous phase and, thus, increasing its release rate. Several authors have shown that the ion-pairing strategy can retain the drug encapsulated in the nanocarrier after intravenous administration, resulting in improved pharmacokinetics [25–27]. Then, the drug release would be accelerated by the relatively low pH surrounding the tumor tissue or by the acidic environment inside the endosomes and lysosomes of tumor cells, favoring the target release of DOX from the NLC [20,28].

View all citing articles on Scopus

Unspecified

View full text